— Know what they know.
Not Investment Advice

SPRO NASDAQ

Spero Therapeutics, Inc.
1W: -3.2% 1M: -2.5% 3M: -45.7% YTD: -49.4% 1Y: -39.3% 3Y: -0.8% 5Y: -93.7%
$1.19
-0.07 (-5.56%)
 
Weekly Expected Move ±11.7%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 58 · $68.9M mcap · 46M float · 2.86% daily turnover · Short 32% of daily vol

Balance Sheet Trends

Total Assets
$69M -37.7% ▼
5Y CAGR: -14.8%
Total Liabilities
$10M -84.6% ▼
5Y CAGR: -14.3%
Shareholders Equity
$59M +28.0% ▲
5Y CAGR: -14.9%
Cash & Investments
$40M -23.9% ▼
5Y CAGR: -20.5%
Total Debt
$3M -32.6% ▼
5Y CAGR: -18.1%
Net Debt
-$37M +23.1% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$113M$109M$76M$53M$40M
Short-Term Investments$34M$0$0$0$0
Cash & ST Investments$146M$109M$76M$53M$40M
Net Receivables$3M$1M$51M$52M$25M
Inventory$0-$4M$0$0$0
Other Current Assets$0$3M$4M$2M$2M
Total Current Assets$158M$109M$131M$107M$67M
Property, Plant & Equip.$8M$5M$4M$3M$1M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$47M$0$0
Other Non-Current Assets$6M$10M$435K$153K$153K
Total Non-Current Assets$13M$16M$51M$3M$2M
Total Assets$171M$125M$182M$111M$69M
— Liabilities —
Accounts Payable$1M$617K$1M$7M$693K
Short-Term Debt$0$0$2M$0$2M
Deferred Revenue$2M$10M$27M$22M$258K
Other Current Liabilities$0$0$3M$0$6M
Total Current Liabilities$19M$22M$37M$49M$9M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$49M$96K$87K$576K$91K
Total Non-Current Liabilities$64M$27M$38M$15M$1M
Total Liabilities$83M$49M$75M$64M$10M
— Equity —
Common Stock$32K$52K$53K$55K$56K
Retained Earnings-$367M-$414M-$391M-$460M-$451M
Accumulated OCI-$2K$0$0$0$0
Total Stockholders Equity$88M$76M$107M$46M$59M
Total Liabilities & Equity$171M$125M$182M$111M$69M
— Key Metrics —
Total Debt$7M$7M$6M$4M$3M
Net Debt-$105M-$102M-$71M-$49M-$37M
Total Investments$34M$0$47M$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms